Cypre Status
The company raised $150,000 of convertible debt funding from undisclosed investors on August 24, 2018. Earlier, the company raised an undisclosed amount of venture funding from Hemi Ventures on January 1, 2017.
Developer of a tumor microenvironment system intended to be used for the transformative 3D cellular research and clinical testing of cancer patients. The company's tumor microenvironment system consists of extracellular matrix remodeling, immune infiltration and other processes that influence tumor progression, enabling medical institutions with better and advanced drugs, opening the door for a new generation of therapeutics and patient success.
Year Founded
2016
General Information
-
Website
-
Business Status
Generating Revenue
-
Ownership Status
Privately Held (backing)
-
Financing Status
Venture Capital-Backed
Cypre News and Updates
Bridge IC Solutions Market is Expected to Reach US$ 43.33 Bn by ...
Rejoice Magazine | January 26, 2023
UHV announces fall 2022 president's, deans' lists | Reader Stories ...
Victoria Advocate | January 22, 2023
SLB sees Guyana, Suriname helping drive offs...
BNamericas English | January 20, 2023
SLB Announces Fourth-Quarter and Full-Year 2022 Results
StreetInsider.com | January 20, 2023
Gardiala tops Auctav's ML Bloodstock Sale at €66,000
Racing Post | January 19, 2023
Artmarket.com: must-know results in 2022, according to Artprice
Business Upturn | January 12, 2023
Cypre's Verticals
Cypre Primary Industry Sector / Group / Code
Cypre's Trends
Cypre Metrics
Majestic Referring Domains
Headquarters
-
HQ Address Line 1953 Indiana Street
-
HQ CitySan Francisco
-
HQ State/ProvinceCalifornia
-
HQ Post Code94107
-
HQ CountryUnited States
Cypre's Keywords
mood_badFeed is empty.
Add a review